For 30 days, 50 women with primary fibromyalgia syndrome reported daily progress and effort toward a health-fitness and a social-interpersonal goal and the extent to which their pain and fatigue hindered their accomplishment. They also carried palmtop computers to assess their sleep and their pain, fatigue, and positive and negative mood throughout the day. Analyses of the person-day data set showed that on days during which pain or fatigue increased from morning to evening, participants perceived their goal progress to be more attenuated by pain and fatigue. Unrestorative sleep the night before predicted the following day's effort and progress toward accomplishing health-fitness goals, but not social-interpersonal goals. Finally, participants who reported more progress toward social-interpersonal goals on a given day were more likely to evidence improvements in positive mood across the day, regardless of any changes in pain or fatigue that day.
From a biopsychosocial perspective, assessing chronic pain's psychological impact should involve at minimum the measurement of pain severity, functional interference, and pain-related emotional burden. This article details the development of a brief instrument, the 15-item Profile of Chronic Pain: Screen (PCP:S), designed to address these three key elements in a national (US) sample of over 2400 individuals recruited via random digit dialing. Retest reliability, internal consistency, and preliminary validity were excellent. The scales also demonstrated minimal social desirability response bias. A series of confirmatory factor analyses on several distinct samples revealed a stable, 3-factor solution reflecting pain severity, interference, and emotional burden. Finally, national norms were developed by gender and three age groups. In view of its strong psychometric properties, the PCP:S has the potential to serve as a brief, cost-effective assessment tool for identifying individuals whose chronic pain merits more detailed psychosocial evaluation.
The aim of the present research was the development and validation of a set of instruments, collectively called the Profile of Chronic Pain: Extended Assessment Battery (PCP:EA), designed to be administered to adults (between the ages of 25 to 80) after establishing the existence of a chronic pain problem. The final 86-item version of the PCP:EA consisted of 33 single items assessing: pain location and severity, pain characteristics (e.g. worst daily pain), medication use, health care status, the identity of the most important person in the patient's life, and functional limitations in 10 areas of daily living. In addition, the PCP:EA includes 13 multi-item subscales addressing aspects of coping (guarding, ignoring, task persistence, and positive self-talk), catastrophizing, pain attitudes and beliefs (including disability beliefs, belief in a medical cure for pain, belief in pain control, and pain-induced fear), and positive (tangible and emotional) and negative (insensitivity and impatience) social responses. Data were obtained from two national samples which were recruited and screened via a random-digit dialing telephone interview procedure. Stratified sampling was employed to assure equal gender and age group representation across three age groupings (25-44; 45-64; 65-80). Two survey studies provided strong evidence for the hypothesized factor structure, internal consistency, independence from response bias, and validity of the PCP:EA. Moreover, the presence of normative data enhance the diagnostic and prescriptive utility of the instrument.
Psychosocial dimensions of chronic pain differed between community-residing African American and Caucasian adults surveyed as part of a national sample.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.